Quicksilva Software Solutions has secured a deal with life sciences specialists Applied InSilico to deploy their artificial intelligence-based data mining tool called ELE, the Evolutionary Learning Environment, globally.
ELE is a data analysis tool capable of reviewing huge and complex volumes of information quickly. This enables it to uncover relationships between diseases and genes and consequently allow faster development of safe drug treatments.
Healthcare systems and services specialists, Quicksilva see the tool as something which can help speed up pharmaceutical research quickly, which will be of increasing use to the public health sector.
Managing director, Gayna Hart, told E-Health Insider: “The private sector jump for this potential. Quicksilva is keen to help Public Health keep up with developments.”
She added that the system would enable pharmacists to have access to the very latest pharmaceutical research.
Hart added: “When you think about the recent National Audit Office report telling trusts that better information is needed to perform more cost-effective prescribing, it stands to reason that trusts need something to guide them to options available to them.
“ELE can keep prescribing affordable by sorting through all the pharmaceutical research with a cost-effective solution. It could even help to alleviate the problems we often hear about postcode lottery drugs.”
The predictive modelling process uses data to predict future behaviour and probable outcomes. Key variables likely to influence this future behaviour are identified and historical data analysed.
The system is already used by established drug manufacturers GlaxoSmithKline and Quicksilva are now targeting other pharmacy giants to use the new technology.
Hart said: “There is a wealth of information available about various diseases and their correlation with certain genes, but for an individual to wade through that volume of information to make a link is like looking for a needle in a haystack. ELE is helping healthcare treatment advance at a quicker pace and the main beneficiary is the patient.”
Quicksilva have added the product to their existing range of services and say interest has been high.
Links